AdipoRon for the treatment of type 2 diabetes in mice and its possible mechanism of the liver

Abstract

To observe the effect of AdipoRon for the treatment of type 2 diabetes (T2DM)in mice and its effect on the liver. Forty male C57/BL6 mice (SPF) were randomly divided to normal control (NC) group and the experimental group. To establish the T2DM mice model, mice in the experimental group were fed with high fat and high glucose, combined with intraperitoneal injection of streptozotocin (STZ) in small doses, and mice were further subdivided into model control (DM) group, model control with low AdipoRon (DM+L) group and model control with high AdipoRon (DM+H) group (n=10). Serum indexes, such as levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) were detected biochemically and the morphological changes of liver cells were observed with HE staining and expression of liver carbohydrate related gene (PEPCK) were determined by real-time fluorescence quantitative PCR (real time FQ-PCR). Compared with mice in the DM group, levels of ALT, AST, ALP, triglyceride (TG), glucose (GLU) reduced in DM+L and DM+H group (P<0.05). Concentrations of serum free fatty acids (FFA) in DM+L and DM+H group reduced significantly (P<0.05). Besides, concentrations of liver glucose-6-phosphatase (G-6-P) in the mice of DM+L group reduced significantly, while there was no significant difference in the content of G-6-P between the mice of DM+H group and the mice of DM group. Furthermore, the expression of the liver phosphoenolpyruvate carboxylase (PEPCK) in the DM+H group reduced significantly (P<0.05). Compared with the DM group no significant change was found in the PEPCK expression between DM+L and DM group. The serum indexes such as levels of ALT, AST, ALP, TG, Glu, G-6-P and PEPCK were all reduced in DM mice treated with AdipoRon, indicating the obvious protecting effect of AdipoRon on the liver in DM mice.